Cartesian Therapeutics (RNAC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum ...

5. The guidance recommends advanced or immunomodulatory therapy after failure of 5-aminosalicylates instead of a "step-up" approach. The recommendations also define moderate to severe disease using a ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

GUANGZHOU -- The China-Italy Joint Laboratory of Pharmaceutical Biotechnology and Immunosafety has been launched in South ...